Casey, Kerry A https://orcid.org/0000-0001-7194-8585
Guo, Xiang https://orcid.org/0000-0001-6441-5174
Smith, Michael A
Wang, Shiliang
Sinibaldi, Dominic
Sanjuan, Miguel A
Wang, Liangwei
Illei, Gabor G
White, Wendy I
Clinical trials referenced in this document:
Documents that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
SAT0243 Exposure-response (E-R) analysis for selection of optimal dosage regimen of anifrolumab in patients (PTS) with systemic lupus erythematosus (SLE)
https://doi.org/10.1136/annrheumdis-2017-eular.3517
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
Type I interferon receptor blockade with anifrolumab corrects innate and
adaptive immune perturbations of SLE
https://doi.org/10.1136/lupus-2018-000286
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
https://doi.org/10.1136/annrheumdis-2017-212504
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2018-000284
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus
https://doi.org/10.1136/lupus-2016-000179.75
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
Documents that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
SAT0243 Exposure-response (E-R) analysis for selection of optimal dosage regimen of anifrolumab in patients (PTS) with systemic lupus erythematosus (SLE)
https://doi.org/10.1136/annrheumdis-2017-eular.3517
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
Type I interferon receptor blockade with anifrolumab corrects innate and
adaptive immune perturbations of SLE
https://doi.org/10.1136/lupus-2018-000286
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
https://doi.org/10.1136/annrheumdis-2017-212504
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2018-000284
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus
https://doi.org/10.1136/lupus-2016-000179.75
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
Documents that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
SAT0243 Exposure-response (E-R) analysis for selection of optimal dosage regimen of anifrolumab in patients (PTS) with systemic lupus erythematosus (SLE)
https://doi.org/10.1136/annrheumdis-2017-eular.3517
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
Type I interferon receptor blockade with anifrolumab corrects innate and
adaptive immune perturbations of SLE
https://doi.org/10.1136/lupus-2018-000286
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
https://doi.org/10.1136/annrheumdis-2017-212504
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2018-000284
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus
https://doi.org/10.1136/lupus-2016-000179.75
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
Documents that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
SAT0243 Exposure-response (E-R) analysis for selection of optimal dosage regimen of anifrolumab in patients (PTS) with systemic lupus erythematosus (SLE)
https://doi.org/10.1136/annrheumdis-2017-eular.3517
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
Type I interferon receptor blockade with anifrolumab corrects innate and
adaptive immune perturbations of SLE
https://doi.org/10.1136/lupus-2018-000286
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
https://doi.org/10.1136/annrheumdis-2017-212504
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2018-000284
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus
https://doi.org/10.1136/lupus-2016-000179.75
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
Funding for this research was provided by:
AstraZeneca/MedImmune